Chemoembolization for liver metastases from medullary thyroid carcinoma

Area of Science:

• Interventional Radiology
• Oncology
• Hepatobiliary Malignancies

Background:

• Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor with limited treatment options for advanced disease.
• Distant metastases, particularly in the liver, are a primary cause of mortality in MTC patients.
• Systemic chemotherapy and somatostatin analogs show poor efficacy in controlling MTC progression and symptoms.

Observation:

• The study evaluated the impact of liver transarterial chemoembolization (TACE) in twelve MTC patients with progressive liver metastases.
• Patients underwent a mean of 1.5 TACE procedures, with tumor response assessed using RECIST criteria.
• Symptomatic response was defined as a >25% decrease in symptom intensity.

Findings:

• Partial radiological tumor response was observed in 42% of patients, with a median duration of 17 months.
• Disease stabilization occurred in 42% of patients for a median of 24 months; progression in 16%.
• Partial responses were more frequent in patients with <30% liver involvement; clinical response noted in diarrhea patients.

Implications:

• Transarterial chemoembolization (TACE) is a viable treatment option for medullary thyroid carcinoma (MTC) with liver metastases.
• TACE should be considered early in the course of metastatic disease, especially with predominant liver involvement.
• Further research may explore TACE in combination with other therapies for improved MTC management.